BioWorld

Dec. 10, 2004

Nastech Triples Cash With Public Sale Worth $57.4M

Padding its savings account and then some, Nastech Pharmaceutical Co. Inc. raised about $57.4 million in gross proceeds through a public offering. (BioWorld Today) Read More

Dynavax's Phase II/III HBV Data Supportive; Phase III Trials Next

Putting Nobel Prize-Winning Proteasome Research To Use

With $62M Offering, Array Can Push More Into Clinic

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...